Landos Biopharma Inc

Landos Biopharma — Investor Presentation (January 2024)

31 slides from Landos Biopharma's investor presentation, Jan 4, 2024

  1. Slide 1: Corporate Overview

    January 2024 Clinical stage biopharmaceutical company focused on developing first-in-class, oral therapeutics for autoimmune disease Corporate Overview Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, pla

  3. Slide 3: Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC

    Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC NASDAQ: LABP Potentially transformative oral, once-daily therapy for moderate to severe ulcerative colitis (UC) Immunometabolism addresses multiple causes of UC through novel, bimodal MOA targeting NLRX1 Promising s

  4. Slide 4: Landos Pipeline Focused on Novel, Immunometabolic Targets

    Landos Pipeline Focused on Novel, Immunometabolic Targets Need a footnote describing the relationship with JH, also likely need a footnote for LianBio CANDIDATE INDICATION PRECLINICAL PRE-IND PHASE I PHASE II PHASE III NLRX1 Pathway NX-13 Ulcerative Colitis Crohn’s Disease LABP-66 Multiple Sclerosis

  5. Slide 5: Therapeutic Challenges Present Large Unmet Need for UC Patients

    Therapeutic Challenges Present Large Unmet Need for UC Patients Relapse Ulcerative Colitis Chronic colonic inflammation with rectal bleeding and diarrhea Patients experience relapsing (flares) and remitting episodes of disease severity Therapeutic Goals Induce and maintain steroid-free symptom relie

  6. Slide 6: NX-13 Unique Bimodal MOA Activates NLRX1 Pathway for Treatment of UC

    NX-13 Unique Bimodal MOA Activates NLRX1 Pathway for Treatment of Ulcerative Colitis (UC) Leber et al. J Immunology 2019 NX-13 is an oral, once-daily therapy being developed for moderate-to-severe UC Novel NLRX1 agonist Bimodal MOA aims to reduce reactive oxygen species intracellularly and inflammat

  7. Slide 7: Mechanism of Action

    Mechanism of Action

  8. Slide 8: Immunometabolism May Play a Critical Role in Breaking the Therapeutic Ceiling

    Inflammatory Signaling Cellular Metabolism Immunometabolism May Play a Critical Role in Breaking the Therapeutic Ceiling of Current Treatments Cellular metabolism is a central regulator of the activation and function of immune cells Dual effects to control both the intracellular metabolic environmen

  9. Slide 9: Immune Function is Intimately Tied to the Intracellular Environment of Processing & Using Energy

    Immune Function is Intimately Tied to the Intracellular Environment of Processing & Using Energy The intracellular immunometabolic state (the processing & using of energy through glycolysis or mitochondrial metabolism) provides a baseline, and can affect cellular response as pro- or anti-inflammator

  10. Slide 10: The Role of Immunometabolism in Immunology & UC

    The Role of Immunometabolism in Immunology & UC Immunometabolic response in inflammatory diseases in the immunology universe & UC: Abnormal or imbalanced immune activation of the response resulting in over abundance of pro-inflammatory cells & cytokines with lack of anti-inflammatory control. In UC,

  11. Slide 11: Current Therapies Focus Exclusively on Extracellular Actions or Signals

    Current Therapies Focus Exclusively on Extracellular Actions or Signals Falling Short of Effectively Treating a Multifactorial Disease Like UC Global Data Report GDHC271PIDR; Chi, Cell & Mol Immuno 2022 Drug Classes MOA Extracellular (External) Intracellular (Internal) Environment Drug Classes MOA C

  12. Slide 12: Bimodal Targeting of the Intracellular Environment & Extracellular Inflammatory Response

    Bimodal Targeting of the Intracellular Environment & Extracellular Inflammatory Response Aims to Control Multiple Factors in the UC Inflammation Cycle O’Neill et al. Nat. Rev. Immunol. 2016; Bittencourt et al. Inflammm Bowel Dis 2021; Chi, Cell & Mol Immuno 2022; ROS: Reactive Oxygen Species Metabol

  13. Slide 13: NX-13 Bimodal MOA Addresses Both Extracellular Signals and Intracellular Environment

    NX-13 Bimodal MOA Addresses Both Extracellular Signals and Intracellular Environment to Reduce UC Inflammation Cycle Leber et al. J Immunology 2019; Leber et al. Front. Immuno 2018 Broad immune balance disfavors pro-inflammatory cells and cytokines with enhanced anti-inflammatory control Improved ep

  14. Slide 14: NX-13 Pre-Clinical / Clinical Data & Phase Trial Design

    NX-13 Pre-Clinical / Clinical Data & Phase 2 Trial Design

  15. Slide 15: Pre-Clinical Data Suggests NX-13 Potential to Broadly Reprogram Immune Response

    Pre-Clinical Data Suggests NX-13 Potential to Broadly Reprogram Immune Response *DSS colitis data shown. Similar data in the CD45RBhi adoptive transfer colitis & Mdr1a-/- colitis models. See Leber et al., J Immunol 15 December 2019; 203 (12): 3407–3415 for more information. Reduced disease activity

  16. Slide 16: Phase 1b Study Design of NX-13 in Active UC

    Phase 1b Study Design of NX-13 in Active UC IR = Immediate Release; MR = Modified Release; MES = Mayo Endoscopic Score; FCP = Fecal Calprotectin; EOT = End Of Treatment Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only 4 Weeks

  17. Slide 17: Phase 1b Results: Favorable Endoscopic and Histologic Responses After 4 Weeks

    Phase 1b Results: NX-13 Demonstrated Favorable Endoscopic and Histologic Responses with Reductions in Multiple Clinical Measures After 4 Weeks Primary endpoints were safety and tolerability; Exploratory endpoints were efficacy and biomarkers; IR= Immediate Release; MR= modified release designed to d

  18. Slide 18: Phase 1b Results: Fast Onset of Action in Rectal Bleeding & Stool Frequency

    Phase 1b Results: Fast Onset of Action for NX-13 Supported Symptomatic Remission in Rectal Bleeding & Stool Frequency Rectal Bleeding Change from Baseline Stool Frequency Change from Baseline Placebo NX-13 500 mg MR NX-13 500 mg IR NX-13 250 mg IR Placebo NX-13 500 mg MR NX-13 500 mg IR NX-13 250 mg

  19. Slide 19: Phase 1b Results: NX-13 Was Well-Tolerated & Shows Promising Signs of Clinical Improvement

    Phase 1b Results: NX-13 Was Well-Tolerated & Shows Promising Signs of Clinical Improvement in Active UC Note: Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only NX-13 induced early signs of clinical improvement in patient’s symptoms

  20. Slide 20: NEXUS Phase 2 Proof of Concept Trial

    NEXUS Phase 2 Proof of Concept Trial ClinicalTrials.gov Identifier: NCT05785715 Key Design Principles Blinded Powered Placebo Controlled Dose-Ranging Goal Evaluate safety, efficacy and pharmacokinetics of NX-13 in moderate to severe UC patients in 12-week induction trial Timing Initiated in Q2 2023;

  21. Slide 21: NEXUS Phase 2 Proof of Concept Study Design

    NEXUS Phase 2 Proof of Concept Study Design: NX-13 in Moderate to Severe UC Randomization n=80 Inclusion1 Moderate to Severe UC R NX-13 250mg IR n=32 NX-13 750mg IR n=32 Placebo n=16 Week 12 Week 52 EOT Day 1 Randomization Visit Induction Treatment Period 12 Weeks Long-Term Extension 40 Weeks R Rand

  22. Slide 22: Market & NX-13 Positioning

    Market & NX-13 Positioning iA ! ; Ane: “UR — Ss wy) WN 08 Bi oY RX la RS SS (SACKING psi fD SZ we. | i \ 4 |

  23. Slide 23: Attractive & Growing Market Opportunity in UC

    Attractive & Growing Market Opportunity in UC 1 November 2022 Clarivate UC Disease Landscape & Forecast; 2 April 2023 Global Data Ulcerative Colitis: Eight-Market Drug Forecast & Market Analysis 2021-2031; Severe category includes fulminant Global UC Sales1 Global UC Diagnosed Patients1 Largest mark

  24. Slide 24: NX-13 Poised for Broad Utilization in Both Early & Late-Stage Disease

    NX-13 Poised for Broad Utilization in Both Early & Late-Stage Disease Potential benefits may help transform the current treatment paradigm: Gut selective allowing target engagement with the GI tract Novel, first-in-class MOA with convenient, oral, once-daily dosing MOA may allow for improved efficac

  25. Slide 25: Landos Pipeline Focused on Novel, Immunometabolic Targets

    Landos Pipeline Focused on Novel, Immunometabolic Targets Need a footnote describing the relationship with JH, also likely need a footnote for LianBio CANDIDATE INDICATION PRECLINICAL PRE-IND PHASE I PHASE II PHASE III NLRX1 Pathway NX-13 Ulcerative Colitis Crohn’s Disease LABP-66 Multiple Sclerosis

  26. Slide 26: Future NLRX1 & PLXDC2 Indications & Programs Provide Growth Potential Beyond NX-13

    Future NLRX1 & PLXDC2 Indications & Programs Provide Compelling Growth Potential Beyond NX-13 in UC 1 Moderate to Severe only; 2 Relapsing-Remitting MS only; 3 Clarivate UC Disease Landscape & Forecast 2023 Ulcerative Colitis Crohn’s Disease Asthma1 Multiple Sclerosis2 Rheumatoid Arthritis WW Annual

  27. Slide 27: Experienced Management Team in Immunology & Drug Development

    Experienced Management Team in Immunology & Drug Development FABIO CATALDI, MD Executive Vice President & Chief Medical Officer DAWN LOURO Vice President, Clinical Operations CLAUDIA LOPEZ, DVM Vice President, Clinical Development GREGORY OAKES President & Chief Executive Officer DAVID PEREIRA, PHD

  28. Slide 28: Top-Tier Advisory Teams

    Top-Tier Advisory Teams GREGORY OAKES President & Chief Executive Officer CHRIS GARABEDIAN Chairman Xontogeny, Perceptive Advisors ROGER ADSETT Chief Operating Officer of Insmed, Inc. ALKA BATYCKY, PH.D. Director FRED CALLORI Xontogeny, Perceptive Advisors TIAGO GIRÃO CFO of Televant Therapeutics TI

  29. Slide 29: Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC

    Landos Biopharma is Singularly Focused on Advancing NX-13 Clinical Development in UC NASDAQ: LABP Potentially transformative oral, once-daily therapy for moderate to severe ulcerative colitis (UC) Immunometabolism addresses multiple causes of UC through novel, bimodal MOA targeting NLRX1 Promising s

  30. Slide 30: Thank you

    Thank you Contact: [email protected]

  31. Slide 31: Appendix: Key Publications

    Appendix: Key Publications (11/23) The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal of Crohn's and Colitis, e-published ahead of print (10/23) The Nucleotide-Binding Oligomerization Domain,

Landos Biopharma — Investor Presentation (January 2024) on 6ix